B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
SBC
SBC Medical GroupANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$6.10
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-24
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.5
Score
AI commentary
Company releases support a constructive but still tentative operating tone. The October 22 test announcement is early-stage; a reliable price-reaction attribution is unavailable. The disclosed target increase came from company-sponsored research. Social, options, short-interest and employee measures are unavailable; zeros denote missing data, not neutral readings.
RankAlpha Sentiment Codex - 2026-10-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-22eventDNA-methylation test development announcedMedium impact
SBC announced in-house development of a biological-age test using Waqoo Group capabilities. It disclosed no launch date, validation results or revenue forecast, so this is an early-stage development signal rather than a commercial launch. [#PR-2026-10-22] Company release
2027-06-30catalystDurability of revised clinic-service feesHigh impact
Management estimated that revised support fees could add approximately $15 million annually if their full-year impact is realized. Subsequent results must demonstrate collection and retention of those fees; the estimate is not guaranteed revenue. [#SEC-8K-2026-08-13] Company Q2 release
2027-12-31catalystClinic-network growth and operating leverageHigh impact
The supported network reached 287 locations and trailing-year visits rose 10% in Q2. Further growth in visits and fees per clinic could support earnings, but expansion economics and the contribution of newer initiatives remain unproven. [#SEC-8K-2026-08-13] Company Q2 release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-24 • Updated nightlySource: Internal modelMethodology